BALYASNY ASSET MANAGEMENT L.P. - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q2 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.

Quarter-by-quarter ownership
BALYASNY ASSET MANAGEMENT L.P. ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q2 2024$5,250,402
+43.9%
207,280
-5.8%
0.01%0.0%
Q1 2023$3,649,092
+1365.5%
220,090
+780.4%
0.01%
+800.0%
Q3 2022$249,000
-33.2%
25,000
-32.0%
0.00%0.0%
Q1 2022$373,000
-54.1%
36,786
-24.5%
0.00%
-66.7%
Q4 2021$812,000
-77.2%
48,700
-2.6%
0.00%
-85.0%
Q4 2020$3,556,00050,0000.02%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$60,317,00040.05%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$308,746,0006.20%
M28 Capital Management LP 513,300$5,102,0005.33%
GREAT POINT PARTNERS LLC 1,050,000$10,437,0002.51%
Octagon Capital Advisors LP 933,743$9,281,0001.60%
HHLR ADVISORS, LTD. 5,362,014$53,298,0001.40%
VIKING GLOBAL INVESTORS LP 26,620,991$264,613,0001.22%
Cormorant Asset Management, LP 1,469,179$14,604,0001.02%
Fernwood Investment Management, LLC 204,550$2,033,0000.86%
TANG CAPITAL MANAGEMENT LLC 585,424$5,819,0000.71%
View complete list of BRIDGEBIO PHARMA INC shareholders